Piperazinyl-propyl-pyrazole derivatives as dopamine d4 receptor antagonists, and pharmaceutical compositions containing the same

A piperazinyl-propyl-pyrazole derivative or its pharmaceutically acceptable salt represented by the following formula 1:

• wherein R1 is a C1-C10 alkyl group, or a substituted or unsubstituted aryl or heteroaryl group;
• one of R2 and R3 is a hydrogen atom, while the other is a C1-C10 alkyl group, benzyl group, or substituted or unsubstituted aryl or heteroaryl group;
• R4, R5, R6 and R7, being same or different with one another, are independently a hydrogen atom or a C1-C10 alkyl group;
• R8, R9, R10, R11 and R12, being same or different with one another, are independently a hydrogen atom, a halogen atom, a C1-C10 alkyl group, a C1-C10 alkoxy group, a bis(substituted or unsubstituted aryl)alkylene group, a benzyl group, a nitro group, a hydroxy group, a cyano group, an amino group, a mono or dialkylamino group, an alkylcarbonylamino group, an aminosulfonyl group, a mono or dialkylaminosulfonyl group, an alkylcarbonyl group, or an alkyloxycarbonyl group;
• the dotted line represents a single bond or a double bond which depends on the substitution of R2 and R3 but maintains the directionality of a pyrazole ring;
• said aryl group represents a phenyl group, said heteroaryl group represents a thiophenyl group or a pyridyl group, and said substituted aryl or heteroaryl group represents an aryl or a heteroaryl group with from 1 to 3 substituents selected from the group consisting of a halogen atom, a nitro group, a C1-C10 alkyl group, a C1-C10 alkoxy group, a C1-C10 haloalkyl group, and a C1-C10 haloalkoxy.